PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET 2024 Cantor Global Healthcare Conference Location: New York City Fireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ET A webcast of the fireside chats will be available on th ...

| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...

Harmony Biosciences Holdings, Inc. (HRMY) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings ...

Company Overview - Harmony Biosciences is a commercial stage biopharma company focused on developing treatments for rare and neurological diseases, with one approved product, WAKIX (pitolisant), for excessive daytime sleepiness in narcolepsy patients [2][11] - The company has a market capitalization of approximately $1.9 billion and its stock trades around $34.00 per share [2] Recent Developments - Harmony has received favorable analyst coverage and recently gained approval for a label extension for WAKIX, which now includes pediatric patients aged 6 years and older [12] - The company has made several acquisitions to expand its pipeline, including Epygenix Therapeutics for $35 million, which adds drug candidates targeting rare epilepsy conditions [8][9] - Harmony also acquired exclusive rights to Bioprojet's sleep disorder therapy, TPM-1116, for $25.5 million, and purchased Zynerba Pharmaceuticals for $200 million, which includes Zygel in Phase 3 development for Fragile X Syndrome [9][10] Financial Performance - For Q2 2024, Harmony reported GAAP earnings of $0.20 per share on revenues of $172.8 million, with WAKIX sales increasing by 29% year-over-year [11] - Operating expenses rose significantly to $119.3 million, primarily due to increased R&D expenses of $63.6 million as the company advances its pipeline [11] - The company maintains a FY2024 sales guidance of $700 million, representing a 22% increase over FY2023 [12] Analyst Sentiment - Analyst opinions are mixed, with Goldman Sachs maintaining a Sell rating, citing slowing patient growth, while Mizuho Securities, Needham, and Oppenheimer reiterated Buy ratings with price targets ranging from $52 to $56 [14] - The company ended the first half of 2024 with nearly $435 million in cash and marketable securities, alongside long-term debt of just over $170 million [14] Future Outlook - Analysts project profits to rise slightly to $2.18 per share in FY2024, with significant growth expected in FY2025, estimating profits of $3.67 per share on sales growth of 18% [15] - Management believes that the newly acquired assets could add $1 billion to $2 billion in peak sales if developed successfully, with WAKIX having at least $1 billion in peak potential revenues [15]

Harmony Biosciences Holdings, Inc. (HRMY) closed the last trading session at $35.09, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $43.88 indicates a 25.1% upside potential. The average comprises eight short-term price targets ranging from a low of $28 to a high of $56, with a standard deviation of $10.20. While the lowest estimate indicates a decline of 20.2% from t ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these ...

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 600%. A quarter ago, it was expected that this company would post earnings of $0.64 per share when it actually produced earnings of $0.67, delivering a surprise of 4.69%. Over the last ...

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment o ...

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic (PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld Again - U.S. Patent and Trademark Office (USPTO) Issues Final Denial After Two Attempts to Challenge the WAKIX Patent Received U.S. Food and Drug Administration (FDA) Approval and Launched WAKIX for the Treatment o ...